Literature DB >> 15136301

Prolonged QTc interval and risks of total and cardiovascular mortality and sudden death in the general population: a review and qualitative overview of the prospective cohort studies.

Alicia Montanez1, Jeremy N Ruskin, Patricia R Hebert, Gervasio A Lamas, Charles H Hennekens.   

Abstract

BACKGROUND: In certain subgroups of patients, prolongation of the QTc interval may increase total and cardiovascular mortality due to life-threatening ventricular arrhythmias and sudden death. Nonetheless, whether modest prolongation of the QTc interval in the general population has clinical importance remains unclear.
METHODS: We conducted a literature search from 1990 forward to identify all published prospective cohort studies evaluating the association between prolonged QTc interval and risks of total and cardiovascular mortality as well as sudden death. We reviewed each of the studies individually and then conducted a qualitative overview.
RESULTS: The 7 prospective cohort studies identified included 36 031 individuals. There were 2677 (8.7%) individuals with prolonged QTc interval, defined as 440 milliseconds or greater. Whereas 1 study reported no association between prolonged QTc interval and mortality (relative risk, 1.02; 95% confidence interval, 0.70-1.49), the other 6 reported inconsistent associations overall as well as across subgroups defined by various characteristics including age, sex, and comorbidities. The reported associations for both cardiovascular mortality and sudden death were also inconsistent. In the overview, the only consistent findings were for the subgroup of patients with prior cardiovascular disease, in which relative risks ranged from 1.1 to 3.8 for total mortality, from 1.2 to 8.0 for cardiovascular mortality, and from 1.0 to 2.1 for sudden death. Further, in individuals without prior cardiovascular disease, associations were either absent or greatly attenuated; specifically, relative risks ranged from 0.9 to 1.6 for total mortality, from 1.2 to 1.7 for cardiovascular mortality, and from 1.3 to 2.4 for sudden death.
CONCLUSIONS: There was no consistent evidence for increased risks of total or cardiovascular mortality or of sudden death, except perhaps for patients with prior cardiovascular disease. In the general population, if QTc interval prolongation is associated with any increase in mortality, that risk is likely to be small and difficult to detect reliably.

Entities:  

Mesh:

Year:  2004        PMID: 15136301     DOI: 10.1001/archinte.164.9.943

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  61 in total

Review 1.  Atypical antipsychotics: from potassium channels to torsade de pointes and sudden death.

Authors:  Karine Titier; Pierre-Olivier Girodet; Hélène Verdoux; Mathieu Molimard; Bernard Bégaud; Wilhelm Haverkamp; Malcolm Lader; Nicholas Moore
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

2.  The good old drugs!

Authors:  I Ralph Edwards
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

Review 3.  Assessing QT interval prolongation and its associated risks with antipsychotics.

Authors:  Jimmi Nielsen; Claus Graff; Jørgen K Kanters; Egon Toft; David Taylor; Jonathan M Meyer
Journal:  CNS Drugs       Date:  2011-06-01       Impact factor: 5.749

4.  Phenotype of Children with QT Prolongation Identified Using an Institution-Wide QT Alert System.

Authors:  Heather N Anderson; J Martijn Bos; Kristina H Haugaa; Bruce W Morlan; Robert F Tarrell; Pedro J Caraballo; Michael J Ackerman
Journal:  Pediatr Cardiol       Date:  2015-04-07       Impact factor: 1.655

5.  Impact of clinical decision support preventing the use of QT-prolonging medications for patients at risk for torsade de pointes.

Authors:  Atsushi Sorita; J Martijn Bos; Bruce W Morlan; Robert F Tarrell; Michael J Ackerman; Pedro J Caraballo
Journal:  J Am Med Inform Assoc       Date:  2014-10-16       Impact factor: 4.497

6.  Arrhythmias: Epinephrine test for sudden cardiac death--is it too early?

Authors:  J Martijn Bos; Michael J Ackerman
Journal:  Nat Rev Cardiol       Date:  2012-11-13       Impact factor: 32.419

7.  Methadone and the QTc Interval: Paucity of Clinically Significant Factors in a Retrospective Cohort.

Authors:  Gavin Bart; Zachary Wyman; Qi Wang; James S Hodges; Rehan Karim; Bradley A Bart
Journal:  J Addict Med       Date:  2017 Nov/Dec       Impact factor: 3.702

8.  QT interval and long-term mortality risk in the Framingham Heart Study.

Authors:  Peter A Noseworthy; Gina M Peloso; Shih-Jen Hwang; Martin G Larson; Daniel Levy; Christopher J O'Donnell; Christopher Newton-Cheh
Journal:  Ann Noninvasive Electrocardiol       Date:  2012-08-13       Impact factor: 1.468

Review 9.  Drug-induced torsades de pointes and implications for drug development.

Authors:  Robert R Fenichel; Marek Malik; Charles Antzelevitch; Michael Sanguinetti; Dan M Roden; Silvia G Priori; Jeremy N Ruskin; Raymond J Lipicky; Louis R Cantilena
Journal:  J Cardiovasc Electrophysiol       Date:  2004-04

10.  Quality of systematic reviews of observational nontherapeutic studies.

Authors:  Tatyana Shamliyan; Robert L Kane; Stacy Jansen
Journal:  Prev Chronic Dis       Date:  2010-10-15       Impact factor: 2.830

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.